- Home
Clinical trials - page 15

Search for a clinical trial
Filter
Filter
Geographical location
Type of cancer
Refine your search
Age
Phase
Search for a clinical trial
183 result(s)
- Paris, Saint-CloudPOP-ARTA Phase I Study on Tuvusertib (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients;with advanced solid tumors.
FRANCOIS-CLEMENT BIDARD
- Childhood and adolescent cancersParisSelupassPost-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study
ISABELLE AERTS GAJDOS
- Breast cancerParisMK-2870-010An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent;and in Combination with Pembrolizumab Versus Treatment of PhysicianÀs Choice in;Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
DELPHINE LOIRAT
- ParisEGL-001 (EGL-121)First-in-human Trial of EGL-001 in Patients with Selected Advanced And/·or Metastatic Solid Tumors
CHRISTOPHE LE TOURNEAU
- Childhood and adolescent cancersParis I3Y-MC-JPEHA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
ISABELLE AERTS GAJDOS
- ENT/Head and Neck CancersParis, Saint-CloudSURVEILLE HPVNational, multicentre, open-label, randomised, phase II study evaluating HPV circulating DNA as biomarker to detect the recurrence, in order to improve post therapeutic surveillance of HPV-driven oropharyngeal cancers.
JOEY MARTIN
- SarcomasParisTRUSTBintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)
CLEMENT BONNET
- ParisTUMOSSComparative Evaluation of Care Strategies on Dressing Change-induced Bleeding in Patients With Bleeding Malignant Wounds (TUMOSS)
- Breast cancerParisBGB-43395-101Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395 as monotherapy and in combination with other treatments in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors.
MARIE PAULE SABLIN
- Cancers gynécologiquesSaint-CloudE7386-J081-102_(PENT-02)An Open-Label Study of E7386 in Combination With Other;Anticancer Drug(s) in Subjects With Solid Tumors.
DIANA BELLO ROUFAI